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Abstract 
 This thesis describes synthetic studies in the area of alkaloid chemistry, 
specifically, potent anticancer compounds: the tylophorinines. 
   Tylophorinine is a naturally occurring compound found in the Monarch butterfly 
and plants of the genus Tylophora.  Described here is a concise methodology for 
stereoselective synthesis of this compound, and analogs, starting from simple, naturally 
occurring compounds.  The synthetic strategy represents a simplification in synthesizing 
tylophorinines, and would allow numerous other tylophorinines with similar chemical 
structure to be conveniently synthesized in an analogous fashion. 
 Further, the tylophorinines are convenient compounds for determining where a 
cancer cell may be most effectively attacked.  Numerous attempts were made to alkylate 
and then biotinylate a tylophorinine, in the hopes that a cancer protein would be snared, 
leading to the determination of the tylophorinines mode of action in the cancer cell.          
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I. Introduction 
1. Background on cancer 
 
As society progresses, so does its technology and the ability to eliminate or resist 
various diseases.  Among the many accomplishments in various fields over the years, a 
few have stood as prime examples: Watson and Crick’s elucidation for the structure of 
DNA, Salk’s polio vaccine, and Woodward’s synthesis of strychnine.  These incredible 
accomplishments have inspired others to pursue feats in their fields for the betterment of 
society.  However, one disease has eluded many brilliant minds of our time from 
discovering a cure: cancer. 
 Unlike most diseases, cancer is a genetic alteration of the cell, which reproduces 
autonomously and eventually overwhelms and kills the “host”.1 Its causes, although 
widely speculated and argued,1-3 remain an essential “black box.”  Hence the most 
elusive question is: how and why does a cell transform itself into something incompatible 
with the “functional” living system?  As stated, there are many hypothetical answers that 
serve for good theory, but no definitive proof has yet presented itself.  Other questions 
are: how does one destroy a natural mutation without hurting healthy cells in the process?  
And what makes a cancer cell different enough from a healthy cell so that a drug may 
selectively act upon the mutant? 
 Of course, there are numerous striking differences between cancer and healthy 
cells,1-4 the most pronounced of which is the genetic alterations that result leading to two 
primary differences that are apparent across various cell lines.  One is that cancer can use 
the glycolytic pathway, in place of oxygen, almost exclusively in order to survive.3,4  So, 
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much like a fungus, it “eats up” the body’s natural reserves of sugars producing an acidic 
environment.3,4  Typically, normal tissue has a blood pH of 7.4, whereas in cancers have 
pH ranges of 6.5–6.8, with some as low as 5.5.4  Second, cancer cells tend to have higher 
rates of proliferation with respect to normal cells.1-4  Surgery and radiotherapy have been 
relatively unsuccessful in effectively curbing growth while maintaining a reasonable 
standard of living for the patient.  However, pharmaceuticals entering the body to a great 
extent have not been able to make a significant distinction between cancer and normal 
cells.3  Taxol, has been perhaps the brightest accomplishment in the fight against cancer.  
However, its use has been primarily employed in ovarian cancer,5 and although its core 
skeleton may be viewed as a pharmacophore for other types of anti-cancer agents, little 
significant progress has been made since taxol has been introduced into clinical usage.  
But the acidic environment provides an advantage in that alkaloids, being basic, can 
survive by forming salts in cancer cells until the appropriate “receptor” is found whereby 
the alkaloid may interact with and “kill” the cancer cell.   
2. Tylophora alkaloids in cancer 
A few years ago, an Indian group made a suprising discovery.6  They had isolated 
a new series of compounds from plants of the genus Tylophora, the tyloindicine 
compounds, some of which are the most potent antitumor compounds discovered to date.7  
Tyloindicine’s molecular skeleton is represented in Figure 1.  Chemically, tyloindicines 
are represented with an indolizidine ring system fused to a saturated phenanthrene with 
the exocyclic double bond.  The aromatic rings may contain various substitution patterns.  
Initially, the compound in Figure 1 was the one most sought after.  The aromatic system 
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Figure 1. Tyloindicine G  
 
contains four methoxy groups, but the interesting functionality is the allylic hemi–aminal.  
To date there is no procedure to effectively form this functionality.  Thus the need to 
discover efficient synthetic routes to these compounds became imperative in order to 
produce sufficient quantities to effectively study their properties towards cancer.  Scheme 
1 shows the initial attempt at formation of the allylic hemi-aminal.  However, it was later 
proven that double-bond rearrangement occurs leading to phenanthrene ring formation 
and a benzylic alcohol, as shown in Scheme 2.  Fortunately, it was discovered that the 
tylophorinine produced is also a very active agent against cancer.  In pharmacological 
studies, it has been shown that compound 1 (Figure 2), with the S configuration at the 
hydroxy position, is very active as an anti-cancer agent.7   
The tylophorinines differ from the tyloindicines in two respects: 1. the position of 
the double bond forming the fully aromatic phenanthrene system, and 2. an alcohol alpha 
to the phenanthrene ring.  However, the question remains, how exactly do these 
compounds behave in the cancer cell?  
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3. Biotinylation for determination of mode of action 
The previous question was determined to be answered by creating a molecule which is 
known to be active against cancer cells with a “side group” attached that is easily 
detectable by modern methods.  First, given the anti-cancer activities shown by variously 
substituted tylophorine-type alkaloids,8-15 i.e., that substitution on the phenanthrene part 
can be varied and activity preserved, one can assume that the activity primarily resides in 
the indolizidine part of the molecule.  Hence, it was decided that the detection system 
should be furthest away from this region.  Thus, second, a link between the active 
molecule and detection system was necessary.   This part of the molecule was determined 
to consist of a six-membered aliphatic chain as the most effective bridge.16 Third, 
employment of the biotin–avidin complex was determined to best suit the detection 
system because it is very strong and easily quantifiable17-19.  The biotin–avidin complex 
is often used for cytochemical localization and isolation of receptor studies.  Finally, an 
 6 
amide bond between the linker chain and the biotin was determined to be the proper 
functionality due to its strength and resistance to many chemical environments.  Thus, the 
structure of the target compound is represented by Figure 3. 
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Figure 3. Biotinylated tylophorinine  
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II. Statement of Problem 
1. Methodology for tylophorinine synthesis 
It was found that the active tylophorinine was first synthesized by Rapoport.20 
However, the procedure leading to the compound lacked necessary details for efficient 
production.  Hence, it was determined that we needed to develop a similar synthetic route 
that would facilitate production for the desired tylophorinine, as well as tylophorinines 
with varying aromatic substitution patterns.   
2. Biotinylation of tylophorinine 
To produce the biotinylated tylophorinine, Figure 3, the modified Rapoport 
procedure was employed.  In the course of study, several problems arose that required 
further modification, for example, the oxidative coupling strategy.  More importantly, a 
linker arm was required that would alkylate the phenolic hydroxy group at an appropriate 
position in the synthesis while maintaining the overall synthetic design.  It was 
determined that the alkylation of the alkaloid should occur following cyclization of the 
basic molecular skeleton.  This was done in order to avoid numerous difficult protection 
and deprotection strategies.  The procedure would then be followed to completion 
forming the desired tylophorinine with one step remaining to link with biotin.                  
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III. Results and Discussion 
1. Preparation of S-hydroxytylophorinine 
Repeating Rapoport’s synthesis20 was a primary concern, since the effectiveness 
of the procedure had to be proven.  It was found in the course of preparation that 
simplifications could be made (Scheme 3).  For example, the preparation of 2 proved to 
essentially be a one-pot reaction with only minor separations necessary.  It was found that 
the amine was not separable from the amide, but the amide could be purified since self- 
condensation is essentially irreversible.  Ester hydrolysis to 3, followed by cyclization to 
4, provides the core indolizidine ring skeleton of the tylophorinine.  Stereoselective 
reduction of the ketone employing L-Selectride yields compound 5.  The Rapoport 
paper20 extensively explains the identification between the α and β isomers.  Finally, 
reduction of the amide gives the biologically active compound 1.  In repeating this 
procedure, reproducible spectra were obtained which further validated the use of this 
procedure.  With this information it became possible to develop a strategy towards the 
synthesis of the biotin-linked compound in Figure 3.                     
2. Synthetic studies toward tylophorinine biotinylation 
a. Synthesis of free hydroxy tylophorinine 
 The synthesis as depicted in Scheme 4 opens with a condensation to form a cis–
stilbene system, 6. 3-(4-Acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic 
acid.21  Fieser mentions that the reaction’s cis/trans ratio for this type of reaction is 
approximately 10 to 1.22  However, the condensation was performed without methoxy-
substituted aromatic rings.  In the process the phenolic hydroxy group is acetylated, 
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which helps to avoid future problems associated with this synthesis.  The NMR spectrum 
of the purified compound showed no additional signals to indicate that any significant 
amount of the trans compound was produced.  Alternatively, it is conceivable that the 
trans compound does not recrystallize.  Second and third crops from the mother liquor 
that were recrystallized also produced identical results.  In either case, the intended goal 
of synthesizing pure cis compound is effectively accomplished. 
 Formation of the 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-
methoxyphenyl)acrylic acid methyl ester (7) by standard Fischer esterification procedure 
proceeds in high yield.21  Ester formation is necessary for the preparation of the 
phenanthrene ring since carboxylic acids and some types of free alcohols tend to react 
with reagents that promote the reaction.  A methyl ester was chosen because it is easily 
reducible to the corresponding alcohol.  The acetyl group is also lost in the process.  This 
forms the phenolic hydroxy group which is necessary for iron(III) chloride to react 
effectively.  This provides an inexpensive method to phenanthrene ring formation.   
The phenanthrene ring system is a central component of the tylophorinines.  Its 
formation early in the synthesis is important because it allows manipulation to form the 
indolizidine ring system without potential decomposition and side reactions associated 
with the stilbene ring system.  The phenolic hydroxy group presents problems here, 
however.  Typically in modern syntheses VOF3 is the preferred reagent for bridging the 
phenyl rings.23-26  Hydroxy groups interfere with the action of VOF3 probably by reacting 
with the vanadium  (use of VOF3 in this synthesis is discussed further in section III.2.b) 
itself in a manner that completely destroys the reagent.  This problem is overcome with 
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the use of FeCl3·6H2O.27,28  The iron(III) chloride specifically reacts with 
phenolichydroxy groups in phenolic couplings.  This bondng activates the aromatic 
system with electron donation from the iron, thus producing, 3-hydroxy-2,6,7-
trimethylphenanthrene-9-carboxylic acid methyl ester (8).  At the expense of time, the 
advantage to this reaction is its low cost.   
 Reduction of compound 8 to 9-hydroxymethyl-2,6,7-trimethoxyphenanthren-3-ol 
(9) is performed with LiAlH4.29  The reaction proceeds smoothly with no side-product 
formation.   
 The next series of reactions in Scheme 4, intermediates depicted in Scheme 5, 
introduces the nitrogen to form, 1-(3-hydroxy-2,6,7-trimethoxy-phenanthren-9-ylmethyl)-
5-oxo-pyrrolidine-2-carboxylic acid methyl ester (10), at the primary alcohol position.  It 
commences with bromide formation by alcohol displacement on to give 9a.30  This 
displacement proceeds smoothly and in high yield.  The only drawback is that the excess 
phosphorus must be removed for introduction of the amino acid.  Since the separation is 
between water and chloroform, some of the intermediate bromide compound 9a reverts 
back to the alcohol 9 due to its high reactivity.  Further, upon standing in air, the bromide 
compound 9a begins to decompose.  Fortunately the primary alcohol, much like the 
phenolic alcohol, does not significantly affect the next step despite the basic conditions.  
Thus the 1,3-bis-methoxycarbonylpropylammonium chloride, BMPAC, displaces the 
bromide, forming 9b.20  It would be expected that the nitrogen then condenses directly to 
form the pyrollidinone ring in 10; however, this reaction does not occur to a significant 
extent.  Excess potassium carbonate does not necessarily increase the yield of amide, but 
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surely increases reversion to the alcohol 9.  Fortunately the phenolic hydroxy group does 
not interfere in this reaction to a noticeable extent.  Further purification of the free amine 
9b is futile since it will slowly condense irreversibly on itself over time.  Silica gel 
chromatography is ineffective, since it catalyzes this reaction, but interestingly the 
reaction does not proceed by simply stirring silica with a crude mixture of amine.  Only 
upon column chromatography does this reaction occur.  However, the crude mixture of 
9b may be converted to the amide 10 by heating in a solution of methanol and acetic acid.  
Amide 10 may then be separated from the reformed alcohol 9a by silica gel 
chromatography.  Thus, a convenient method to produce amide 10 has been attained.  
 1-(3-Hydroxy-2,6,7-trimeoxyphenanthren-9-ylmethyl)-5-oxo-pyrrolidine-2-
carboxylic acid (11) is also easily formed20 in short time and high yield.  Because of this 
compound’s insolubilty, all impurities can be washed away with cold water and 
chloroform.  However, the insolubility advantage in this step quickly turns into a 
disadvantage for the remainder of the synthesis.  The result of this problem is evident in 
obtaining the spectra for subsequent compounds.  It is arguable that racemization may 
occur at this stage due to the strong basic conditions of the saponification step, i.e. 
converting 10 to 11.  However, an optical rotation was obtained for 11 that was 
comparable to that for 10.  This supports the contention that the asymmetric center is 
stable under basic reaction conditions.         
The best illustration of solubility problems results with cyclization20 of 11 to 3-
hydroxy-2,6,7-trimethyl-12,12a-dihydro-9H,11H-9a-aza-cyclopenta[b]triphenylene-
10,13-dione (12).  Although 12 is relatively simple to produce, it must be noted that upon 
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formation, the compound almost immediately crashes out of solution.  Column 
chromatography is best suited for purification of this compound, since the compound 
tends to decompose fairly rapidly.  Here, the solubility issue also may raise questions as 
to whether the compound was actually produced.  However, for the purposes of  
identification 12 was converted as shown in Scheme 6, to the acetate 15.  The acetate 15 
could be fully characterized by NMR spectroscopy and mass spectroscopy.   
More importantly an optical rotation was obtained which further supports the 
stability of the asymmetric center, thus showing its relative invulnerability to both basic 
and acidic conditions.  Also, the cyclization itself is a major accomplishment.  Use of 
tin(IV) chloride provides the only effective methodology for cyclization of 11, via the 
acid chloride, to the indolizidine ring system.  Other attempts to cyclize the ring system, 
including traditional reagents, such as aluminum chloride and polyphosphoric acid, 
proved ineffective.   
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Scheme 6. Derivitization of 12 for spectral purposes
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Another of Rapoport’s finer accomplishments in this field was his mention of the 
use of L-Selectride for selective reduction of 12 to 3,13-dihydroxy-2,6,7-trimethoxy-
11,12,12a,13-tetrahydro-9H-9a-aza-cyclopenta[b]triphenylen-10-one (13).  Although he 
does not mention a standard procedure20 for this reaction, it was discovered in the present 
research that the reaction must take place at –10 °C and for 9 hours for maximum 
stereoselectivity.  Disregarding these two provisions causes the (R) hydroxy compound to 
be produced along with amide reduction.  Of the two, the amide reduction poses the 
larger problem, since the two diastereomers are chromatographically separable only so 
long as the amide is present. 
 The end of the synthesis gives way to a simple lithium aluminum hydride 
reduction29 of the amide to produce, 2,6,7-trimethoxy-9,10,11,12,12a,13-hexahydro-9a-
aza-cyclopent[b]tripnylene-3,13-diol (14).  The compound again proved 
spectroscopically difficult to analyze, utilizing TFA to aid in dissolving the compound. 
b. Alternate route to synthesis of free hydroxy tylophorinine  
 It was also of interest to utilize vanadium oxytriflouride (VOF3) as a reagent for 
the purpose of biaryl coupling in this synthesis.  As mentioned, the free hydroxy group 
affects the reaction in such an adverse way the products are indistinguishable.  However, 
with an appropriate protection strategy the problem was quickly overcome.     
The first attempt to overcome the destructive nature of VOF3 on reacting with free 
hydroxy groups was with the use of the methoxymethyl ether as a protecting group.  
Although the reaction was successful in the sense that a useable product 8, was obtained, 
very low yield precludes any further consideration for using this protecting group.  The 
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low yield is attributable to the loss of the ether, which frees the hydroxy group to activate 
the vanadium in some way to destroy the compound.  This was shown after reaction 
workup, where the products were not characterizable. 
The more useful method represented in Scheme 7 shows protection of the 
phenolic hydroxy group in 7 with an acetyl group to 3-(4-acetoxy-3-methoxyphenyl)-2-
(3,4-dimethoxyphenyl)acrylic acid methyl ester (16).  This simple reaction is very high 
yielding.  No purification of product is necessary to proceed to the next step.  
The aromatic coupling to 17 from 16 proceeds in high yield and without loss of 
the acetyl group.  The protecting group, however, does not pose a problem since we are 
able to proceed with simultaneous reduction of both esters to compound 9 in one step.  
Thus we return to a position in the primary sequence to finish the synthesis. 
The advantage to using the vanadium reagent is that of savings in reaction time.  
A coupled product may be produced within one day, whereas the iron chloride requires 
two days, not accounting for purification.  Despite the advantage of using VOF3 in time, 
costs of the reagent may be prohibitive in large-scale production.     
c. Attempts to synthesize the biotin-linked compound 
The simplest conceived route to obtain the desired compound is shown in Scheme 
8.  First the linker arm had to be prepared.  This was done as shown in Scheme 9.  The 
oldest and best known method for amide formation is through an ester to produce 
compound 18, 6-hydroxyhexanoic acid amide.  Since the nitrogen carbonyl bond is 
stronger than the oxygen carbonyl bond, the reaction is essentially reversible, although it   
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does take time.  6-Chlorohexanoic acid amide (19), is then prepared for the alkylation, 
using the chloride as the leaving group.  Attempts to synthesize the bromide, mesyl, or 
tosyl groups as leaving groups proved unsuccessful.  What is even more distressing is 
that despite all attempts to alkylate 12, no product was successfully isolated or 
satisfactorily confirmed.  Many different bases, as well as solvent systems, or no solvent 
systems, were employed.  Bases as strong as sodium hydride were employed.  Other 
bases included NaOH, Cs2CO3, triethylamine, tetrabutylammonium hydroxide, 
diisopropylamine, K2CO3.  Solvents included CH2Cl2, pyridine, acetone, DMF, and 
tetrahydrofuran.  Hence it was decided that the best course of action would be to change 
the linker arm.  This is attributable mainly to two reasons.  The primary cause is believed 
to be steric effects caused by the adjacent methoxy group.  Electronic effects due to the 
aromatic π-system as well as the adjacent oxygen atom also contributed.  This is best 
illustrated with the acetylation to 15, which took approximately 300 equivalents of both 
trimethylamine and acetic anhydride, and three hours at room temperature, for perhaps 
one of the simplest reactions.  Even acetylation to 16 required large molar excesses of 
reagents and at least one hour at room temperature. 
The greatest difficulty in designing the linker arm is that the experimentalist must 
consider the synthesis as a whole.   The best types of linker arms would have to have the 
nitrogen already as the end group in some form.  Two other potential linker arms are 
shown in Figures 4 and 5.  Although the amide was not successfully produced, the nitrile 
could be purchased.  However, even with the more reactive bromide leaving group, the 
alkylation proved unsuccessful, using the conditions previously discussed. 
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H2N
Br
O
NC Br
Figure 4. 6-bromohexanoic acid amide Figure 5. 6-bromohexanenitrile  
 
 
 
d. Future work towards the biotin linkage 
Due to the problems encountered in III.2.c, towards the synthesis of the biotin- 
linked compound, it is apparent that a new route for its synthesis must be developed.  A 
possibility is to alkylate the phenanthrene ring system prior to cyclization of the 
indolizidine ring system.  However, it is difficult to envision an efficient procedure, 
which will compensate for the various reaction condition, as well as maintain functional 
group stability, particularly if a nitrogen containing end group on the linker arm is 
present.                     
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IV. Experimental 
Preparation of (2,3,6,7-tetramethoxyphenanthren-9-ylmethyl)-5-oxo-pyrrolidine-2-
carboxylic acid methyl ester (2).20,30  Compound 9 (1.632 g, 4.970 mmol) was dissolved 
in 100 mL of CHCl3 and cooled to 0 ºC.  A solution of PBr3 (0.7 mL, 7.4 mmol) in 20 
mL of CHCl3 was added dropwise.  The solution was then stirred at room temperature for 
1.5 h, then poured over ice, and the two layers were separated.  The organic phase was 
dried over Na2SO4, filtered, and rotary evaporated, and the product was placed under 
vacuum for 3 h.  The solid was then redissolved in 140 mL of DMF.  Glutamic acid 
dimethyl ester (1.5 g, 7.1 mmol) was added and allowed to stir for 15 min.  K2CO3 (1 g, 
7.2 mmol) was added, and the mixture was allowed to stir at room temperature overnight.  
The solution was then rotary evaporated, and the product was partitioned between CHCl3 
and H2O.  The organic layer was dried over Na2SO4, filtered, and rotary evaporated.  The 
crude product was dissolved in 25 mL of MeOH and 10 mL of HOAc and stirred for 3 h 
at 45 ºC.  The solution was rotary evaporated, and the crude product was purified by 
column chromatography (2:1 hexane:EtOAc) to give 1.145 g of 2 (50.80% yield). 1H 
NMR (CDCl3): δ 2.071 (2 H, m), 2.390 (1 H, m), 2.591 (1 H, m), 3.564 (3 H, s), 3.840 (1 
H, dd, J = 3 Hz, J = 9 Hz), 4.019 (6 H, s), 4.103 (3 H, s), 4.108 (3 H, s), 4.389 (1 H, d, J 
= 14.7 Hz), 5.489 (1 H, d, J = 14.7 Hz), 7.157 (1 H, s), 7.389 (1 H, s), 7.598 (1 H, s), 
7.751 (1 H, s), 7.787 (1 H, s); 13C NMR (CDCl3): δ 22.745, 29.802, 44.777, 52.236, 
55.943, 56.019, 56.106, 56.341, 58.538, 102.746, 103.114, 105.307, 108.229, 124.835, 
124.892, 125.571, 126.918, 127.100, 148.939, 149.098, 149.201, 149.626, 172.276, 
172.276. 
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Preparation of (2,3,6,7-trimethoxyphenanthren-9-ylmethyl)-5-oxo-pyrrolidine-2-
carboxylic acid (3).20 Compound 2 (1.145 g, 2.3345 mmol) was stirred in a solution of 
30 mL of dioxane, 24 mL of MeOH, and 15 mL of 2 N KOH for 1.5 h.  The solution was 
cooled to 0 ºC and 85% H3PO4 was added until pH 4.  The mixture was rotary 
evaporated, and the resulting solid was washed with cold H2O to give 1.003 g of 3 
(90.39% yield).  1H NMR (DMSO-d6): 1.888 (2 H, m), 2.125 (2 H, m), 2.376 (2 H, m), 
3.671 (1 H, d, J = 6.9 Hz), 3.846 (3 H, s), 3.885 (3 H, s), 4.006 (6 H, s), 4.186 (1 H, d, J = 
14.7 Hz), 5.401 (1 H, d, J = 14.7), 7.356 (1 H, s), 7.442 (1 H, s), 7.471 (1 H, s), 7.971 (1 
H, s), 8.013 (1 H, s); 13C NMR (DMSO-d6): δ 22.370, 29.256, 43.666, 55.431, 55.458, 
55.905, 55.966, 57.977, 103.710, 104.298, 104.833, 108.487, 124.175, 124.274, 124.661, 
125.272, 125.776, 126.975, 148.609, 148.707, 148.969, 149.383, 173.224, 174.260. 
Preparation of 2,3,6,7-tetramethyl-12,12a-dihydro-9H,11H-9a-aza-
cyclopenta[b]triphenylene-10,13-dione (4).20  To a solution of 3 (1.003 g, 2.282 mmol) 
in 80 mL of CH2Cl2 was added oxalyl chloride (0.4 mL, 4.6 mmol) and 0.05 mL of DMF.  
The mixture was stirred for 1.5 h then brought to 35 ºC.  SnCl4 (0.5 mL, 4.27 mmol) was 
added, and the mixture was stirred for an additional 4 h.  The solution was cooled to 
room temperature, and 70 mL of cold 2 N HCl was added.  The phases were separated, 
and the organic phase was dried over Na2SO4 and filtered.  The solvent was removed by 
rotary evaporation, and the crude product was purified by column chromatography (99:1 
chloroform:MeOH) to give 818.4 mg of 4 (85.08% yield). 1H NMR (CDCl3): δ 2.570 (3 
H, m), 2.905 (1 H, d, J = 22.2 Hz), 4.067 (3 H, s), 4.075 (3 H, s), 4.111 (3 H, s), 4.148 (3 
H, s), 4.420 (1 H, m), 4.702 (1 H, d, J = 17.7 Hz), 5.731 (1 H, d, J = 17.7), 7.288 (1 H, s), 
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7.762 (1 H, s), 7.784 (1 H, s), 9.082 (1 H, s); 13C NMR (CDCl3): δ 20.776, 30.071, 
40.850, 55.856, 55.909, 56.045, 56.201, 61.202, 102.451, 102.974, 104.226, 107.637, 
121.720, 122.107, 123.371, 124.668, 128.205, 137.542, 149.114, 149.368, 149.925, 
151.986, 174.018, 195.788. 
Preparation of 13-Hydroxy-2,3,6,7-tetramethoxy-11,12,12a,13-tetrahydro-9H-9a-
aza-cyclopenta[b]triphenylen-10-one (5).20  To a solution containing 4 (818.4 mg, 
1.942 mmol) in 20 mL of THF at –10 ºC was added 1 M L-Selectride (2.2 mL, 2.2 
mmol).  The solution was stirred for an additional 5 h, then 0.5 mL of 2 N HCl was 
added.  The solution was partitioned between CHCl3 and H2O.  The organic layer was 
dried over Na2SO4 and filtered, and the solvent was removed by rotary evaporation.  The 
crude product was purified by column chromatography (98:2 chloroform:MeOH) to give 
673.3 mg of 5 (81.88% yield).  1H NMR (CDCl3): δ 2.549 (4 H, m), 3.747 (3 H, s), 3.894 
(1 H, d, J = 8.4 Hz), 4.072 (3 H, s), 4.080 (3 H, s), 4.100 (3 H, s), 4.342 (1 H, d, J = 17.4 
Hz), 5.091 (1 H, d, J = 17.4), 5.117 (1 H, d), 6.742 (1 H, s), 7.591 (1 H, s), 7.663 (1 H, s), 
7.711 (1 H, s); 13C NMR (CDCl3): δ 19.239, 30.842, 40.934, 55.894, 56.053, 58.409, 
65.694, 102.765, 102.910, 103.035, 103.171, 104.283, 122.639, 123.849, 124.240, 
124.414, 124.695, 126.823, 148.795, 149.004, 149.148, 149.322, 175.376. 
Preparation of 2,3,6,7-Tetramethoxy-9,10,11,12,12a,13-hexahydro-9a-aza-
cyclopent[b]tripnylene-13-ol (1).20  To a mixture of LAH (350 mg, 9.22 mmol) in 100 
mL of THF at 0 ºC was added dropwise a solution of 5 (615.3 mg, 1.453 mmol) in 50 mL 
of THF.  The mixture was stirred for 6 h at room temperature then brought back to 0 ºC, 
at which point 25 mL of EtOAc was added dropwise, followed by 50 mL of H2O.  The 
 26 
solution was filtered, and the solvent was removed by rotary evaporation.  The product 
was purified by column chromatography (98:2 chloroform:MeOH) to give 399 mg 1  
(67.06 % yield); 1H NMR (CDCl3): δ 1.801 (2 H, m), 2.095 (3 H, m), 2.362 (1 H, m), 
2.709 (1 H, d, J = 14.4 Hz), 2.950 (1 H, d, J = 13.8), 3.251 (1 H, s), 3.691 (3 H, s), 4.052 
(3 H, s), 4.075 (3 H, s), 4.110 (3 H, s), 4.711 (1 H, s), 5.769 (1 H, s), 7.257 (1 H, s), 7.528 
(1 H, s), 7.873 (1 H, s); 13C NMR (CDCl3): δ 21.565, 23.800, 29.684, 53.006, 55.541, 
55.571, 55.844, 56.148, 64.593, 65.466, 101.840, 102.348, 102.466, 105.277, 122.350, 
123.648, 125.841, 127.400, 147.520, 148.188, 148.324, 148.522; 1H NMR (DMSO-d6 + 
TFA): δ 2.132 (4 H, m), 3.415 (1 H, m), 3.777 (2 H, m), 3.955 (3 H, s), 3.964 (3 H, s), 
4.041 (6 H, s), 4.599 (1 H, dd, J = 8.7 Hz, J = 15.6), 5.146 (1 H, d, J = 12.9), 5.522 (1 H, 
d, J = 1.5 Hz), 7.233 (1 H, s), 7.629 (1 H, s), 8.043 (1 H, s), 8.060(1 H, s); 13C NMR 
(DMSO-d6 + TFA): δ 20.572, 23.079, 51.155, 53.921, 55.594, 55.742, 55.962, 60.731, 
65.872, 103.919, 104.074, 104.279, 105.163, 121.178, 121.831, 123.959, 124.266, 
124.391, 127.279, 148.924, 149.007, 149.269, 149.603. 
Synthesis of 3-(4-Acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic acid 
(6). Vanillin (30.48 g, 200.3 mmol), homoveratric acid (39.48 g, 201.4 mmol), Et3N (70 
mL, 502 mmol), and Ac2O (110 mL, 1163 mmol) were stirred at 100 ºC.  After 24 h the 
mixture was cooled to room temperature, followed by slow addition of 100 mL of H2O.  
Then a solution of 150 g of K2CO3 in 500 mL of H2O was added, and the mixture was 
refluxed until all the solid dissolved.  The mixture was then cooled to room temperature, 
and washed with 2 × 100 mL of Et2O.  The aq layer was then acidified with concd HCl to 
pH 1.  The resulting precipitate was recrystallized from MeOH to give 47.96 g of 6 
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(64.44% yield).  mp 170.9–176.2; 1H NMR (CDCl3): δ 2.259 (3 H, s), 3.440 (3 H, s), 
3.798 (3 H,s), 3.877 (3 H, s), 6.658 (1 H, d, J =  1.8 Hz), 6.639 (1 H, d, J = 1.8 Hz), 6.755 
(1 H, d, J = 2.1 Hz), 6.790 (1 H, dd, J = 1.8 Hz, J = 4.5 Hz), 6.817 (1 H, dd, J = 2.1 Hz, J 
= 4.2 Hz), 6.875 (1 H, d, J = 4.2 Hz), 6.902 (1 H, d, J = 4.2), 7.846 (1 H, s); 13C NMR 
(CDCl3): δ 20.910, 55.603, 56.161, 56.179, 111.668, 112.817, 114,141, 122.408, 
122.917, 124.814, 127.739, 131.347, 133.305, 140.878, 141.819, 149.077, 149.502, 
150.754, 169.053, 173.382 Anal. Calcd for C20H18O6: C, 64.51; H, 5.41. Found: C, 64.63; 
H, 5.50. 
Synthesis of 2-(3,4-Dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid 
methyl ester (7).  Compound 6 (12.03 g, 32.31 mmol) was added to 600 mL of dry 
MeOH.  Concd H2SO4 (12 mL) was added, and the solution was stirred at 65 ºC for 8 h.  
The MeOH was removed by rotary evaporation, and the solid was redissolved in CHCl3 
and washed with satd aq NaHCO3.  The organic phase was dried over Na2SO4, filtered, 
and rotary evaporated.   The solid was purified by column chromatography (2:1 
hexane:EtOAc).  Yield 10.63 g (95.57%).  mp 121.7–123.5; 1H NMR (CDCl3): δ 3.484 (3 
H, s), 3.786 (3 H, s), 3.811 (3 H, s), 3.894 (3 H, s), 5.809 (1 H, s), 6.464 (1 H, s), 6.762 (3 
H, m), 6.867 (1 H, dd, J = 1.8 Hz, J = 8.1 Hz), 6.914 (1 H, d, J = 8.1 Hz), 7.748 (1 H, s); 
13C NMR (CDCl3): δ 52.289, 55.260, 55.844, 111.370, 111.958, 112.763, 114.068, 
122.123, 125.970, 126.884, 128.732, 129.176, 140.562, 145.794, 146.814, 148.453, 
149.170, 168.607 Anal. Calcd for C19H18O5: C, 66.27; H, 5.85. Found: C, 66.11; H, 5.94. 
Synthesis of 3-Hydroxy-2,6,7-trimethylphenanthrene-9-carboxylic acid methyl ester 
(8).  Compound 7 (3.00 g, 8.717 mmol) was dissolved in 400 mL of CH2Cl2.  FeCl3·6H2O 
 28 
(50 g, 185 mmol) was added to 100 mL of CH2Cl2, and the mixture was allowed to stir 
for 48 h.  The solution was filtered, and the solvent was removed by rotary evaporation.  
The crude product was purified by column chromatography (1.5:1 hexane:EtOAc) to give 
1.02 g of 8 (34.39% yield). mp 191.6–193.1 °C; 1H NMR (CDCl3): δ 4.011 (3 H, s), 
4.073 (3 H, s), 4.110 (3 H, s), 4.133 (3 H, s), 5.927 (1 H, s), 7.364 (1 H, s), 7.700 (1 H, s), 
7.739 (1 H, s), 8.341 (1 H, s), 8.615 (1 H, s); 13C NMR (CDCl3): δ 52.336, 56.081, 
56.142, 56.288, 101.852, 102.755, 107.068, 112.715, 122.617, 124.176, 125.235, 
125.463, 127.018, 130.864, 145.552, 149.160, 149.251, 149.327, 168.552.  Anal. Calcd 
for C19H16O5: C, 66.66; H, 5.30. Found: C, 66.39; H, 5.40. 
Synthesis of 9-Hydroxymethyl-2,6,7-trimethoxyphenanthren-3-ol (9).  Method A. To 
a mixture of LAH (3.8226 g, 100.73 mmol) in 300 mL of THF at 0 ºC was added 
dropwise a solution of 8 (5.7829g, 16.892 mmol) in 30 mL of THF.  The solution was 
stirred at room temperature for an additional 4 h, then brought back to 0 ºC, at which 
point 50 mL of EtOAc was added dropwise, followed by 70 mL of 2 N HCl.  The 
solution was filtered, and the solvent was removed by rotary evaporation.  The product 
was purified by column chromatography (1:2 hexane:EtOAc) to give 3.17 g of  9 
(90.44% yield). mp 189.4–192.1 °C  1H NMR (CDCl3): δ 4.026 (3 H, s), 4.035 (3 H, s), 
4.080 (3 H, s), 5.098 (2 H, s), 7.175 (1 H, s), 7.504 (1 H, s), 7.546 (1 H, s), 7.821 (1 H, s), 
7.946 (1 H, s); 13C NMR (CDCl3): δ 55.951, 55.932, 55.951, 64.779, 103.437, 104.587, 
106.024, 107.679, 124.092, 124.498, 125.040, 125.374, 125.469, 131.741, 145.794, 
146.492, 148.795, 148.973 Anal. Calcd for C18H18O5: C, 68.78; H, 5.77. Found: C, 68.73; 
H, 5.89. Method B. A solution of 17 (2.0013 g, 5.207 mmol) in 100 mL of THF was 
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added dropwise to a mixture of LiAlH4 (2 g, 53 mmol) and 30 mL of THF at 0 ºC.  The 
mixture was then warmed to room temperature and stirred for 4 h.  The mixture was 
cooled to 0 ºC, and 60 mL of EtOAc, followed by 40 mL of 2 N HCl were added 
dropwise.  The mixture was filtered and the mother liquor was rotary evaporated.  The 
crude product was purified by column chromatography (1:2 hexane:EtOAc) to give 
1.5474 g of  9 (94.55% yield).  The product was identical with that produced in Method 
A by NMR spectroscopy. 
Synthesis of 1-(3-Hydroxy-2,6,7-trimethoxyphenanthren-9-ylmethyl)-5-oxo-
pyrrolidine-2-carboxylic acid methyl ester (10).  Compound 9 (1.5067 g, 4.7966 
mmol) was dissolved in 100 mL of CHCl3 and cooled to 0 ºC.  A solution of PBr3 (0.7 
mL, 7.4 mmol) in 20 mL of CHCl3 was added dropwise.  The solution was then stirred at 
room temperature for 1.5 h, then poured over ice, and the two layers were separated.  The 
organic phase was dried over Na2SO4, filtered, and rotary evaporated, and the product 
was placed under vacuum for 3 h.  The solid was then redissolved in 140 mL of DMF.  
Glutamic acid dimethyl ester (1.5 g, 7.1 mmol) was added and allowed to stir for 15 min.  
K2CO3 (1 g, 7.2 mmol) was added, and the mixture was allowed to stir at room 
temperature overnight.  The solution was then rotary evaporated, and the product was 
partitioned between CHCl3 and H2O.  The organic layer was dried over Na2SO4, filtered, 
and rotary evaporated.  The crude product was dissolved in 25 mL of MeOH and 10 mL 
of HOAc and stirred for 3 h at 45 ºC.  The solution was rotary evaporated, and the crude 
product was purified by column chromatography (1:1 hexane:EtOAc) to give 1.2093 g of 
10 (57.41% yield). mp 200 °C dec; [α]21.5D 83.56° (CHCl3)  1H NMR (CDCl3): δ 2.042 (2 
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H, m), 2.376 (1 H, m), 2.581 (1 H, m), 3.551 (3 H, s), 3.833 (1 H, dd, J = 3.3 Hz, J = 9.3 
Hz), 4.005 (3 H, s), 4.027 (3 H, s), 4.064 (3 H, s), 4.375 (1 H, d, J = 14.4 Hz), 5.470 (1 H, 
d, J = 14.4 Hz), 7.137 (1 H, s), 7.359 (1 H, s), 7.565 (1 H, s), 7.793 (1 H, s), 7.936 (1 H, 
s); 13C NMR (CDCl3): δ 22.677, 29.764, 44.739, 52.183, 55.822, 55.943, 56.273, 58.512, 
103.270, 105.034, 105.971, 107.497, 124.646, 124.832, 125.162, 125.545, 126.694, 
126.903, 145.968, 146.499, 149.049, 172.269, 174.617.  EIMS: Calcd for C24H25NO7, 
m/z 439.1631; found m/z 439.1622. 
Synthesis of 1-(3-Hydroxy-2,6,7-trimethoxyphenanthren-9-ylmethyl)-5-oxo-
pyrrolidine-2-carboxylic acid (11). Compound 10 (1.0259 g, 2.3345 mmol) was stirred 
in a solution of 30 mL of dioxane, 24 mL of MeOH, and 15 mL of 2 N KOH for 1.5 h.  
The solution was cooled to 0 ºC and 85% H3PO4 was added until pH 4.  The mixture was 
rotary evaporated, and the resulting solid was washed with cold H2O to give 0.9784 g 11 
(98.52% yield).  mp 320 °C dec; [α]21.5D 79.77° (DMSO)  1H NMR (DMSO-d6): 2.370 
(m), 3.652 (d, J = 6.9 Hz), 3.829 (s), 3.905 (s), 3.961 (s), 4.150 (d, J = 13.2 Hz), 5.391 (d, 
J = 14.4), 7.323 (s), 7.401 (s), 7.441 (s), 7.838 (s), 7.941 (s); 13C NMR (DMSO-d6): 
23.005, 29.944, 31.371, 44.350, 56.108, 56.218, 58.570, 104.436, 105.514, 107.638, 
109.217, 124.692, 124.988, 125.250, 125.421, 126.718, 147.851, 148.754, 149.156, 
149.456, 173.939, 174.895.  Anal. Calcd for C23H23NO7·0.5 H2O: C, 63.59; H, 5.57; N, 
3.22.  Found: C, 63.43; H, 5.82; N, 2.92. 
Synthesis of 3-Hydroxy-2,6,7-trimethyl-12,12a-dihydro-9H,11H-9a-aza-
cyclopenta[b]triphenylene-10,13-dione (12).  To a solution of 11 (1.103 g, 2.610 mmol) 
in 80 mL of CH2Cl2 was added oxalyl chloride (0.8 mL, 9.2 mmol) and 0.05 mL of DMF.  
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The mixture was stirred for 1.5 h then brought to 35 ºC.  SnCl4 (1.2 mL, 10.25 mmol) was 
added, and the mixture was stirred for an additional 4 h.  The solution was cooled to 
room temperature, and 70 mL of cold 2 N HCl was added.  The phases were separated, 
and the organic phase was dried over Na2SO4 and filtered.  The solvent was removed by 
rotary evaporation, and the crude product was purified by column chromatography (98:2 
chloroform:MeOH) to give 0.8273 g of 12 (78.32% yield). mp 240 °C; EIMS: Calcd for 
C23H21NO6  m/z 407.1369; found m/z 407.1362. 
Synthesis of 3,13-Dihydroxy-2,6,7-trimethoxy-11,12,12a,13-tetrahydro-9H-9a-aza-
cyclopenta[b]triphenylen-10-one (13).  To a solution containing 12 (328.4 mg, 0.8060 
mmol) in 20 mL of THF at –10 ºC was added 1 M L-Selectride (1.2 mL, 1.2 mmol).  The 
solution was stirred for an additional 5 h, then 0.5 mL of 2 N HCl was added.  The 
solution was partitioned between CHCl3 and H2O.  The organic layer was dried over 
Na2SO4 and filtered, and the solvent was removed by rotary evaporation.  The crude 
product was purified by column chromatography (98:4 chloroform:MeOH) to give 241.8 
mg 13 (73.68% yield).  mp 160 °C dec; [α]21.5D 71.39° (CHCl3)  1H NMR (CDCl3): δ 
2.300 (1 H, m), 2.560 (3 H, m), 3.937 (3 H, s), 4.062 (3 H, s), 4.078 (3 H, s), 4.447 (1 H, 
d, J = 8.4 Hz), 5.130 (1 H, d, J = 1.2), 5.280 (1 H, d, J  = 8.4 Hz), 7.003 (1 H, s), 7.544 (1 
H, s), 7.713 (1 H, s), 7.914 (1 H, s); 13C NMR (CDCl3): δ 19.342, 29.681, 40.896, 55.871, 
56.068, 56.125, 58.269, 65.842, 102.971, 103.300, 103.433, 106.484, 122.601, 123.864, 
124.202, 124.608, 125.033, 126.615, 145.517, 146.924, 149.068, 149.504 EIMS Calcd 
for C23H23NO6 m/z 409.1525; found m/z 409.1520. 
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Synthesis of 2,6,7-Trimethoxy-9,10,11,12,12a,13-hexahydro-9a-aza-
cyclopent[b]tripnylene-3,13-diol (14).  To a mixture of LAH (30 mg, 0.79 mmol) in 15 
mL of THF at 0 ºC was added dropwise a solution of 13 (60 mg, 0.15 mmol) in 10 mL of 
THF.  The mixture was stirred for 6 h at room temperature then brought back to 0 ºC, at 
which point 5 mL of EtOAc was added dropwise, followed by 7 mL of H2O.  The 
solution was filtered, and the solvent was removed by rotary evaporation.  The product 
was purified by column chromatography (98:2 chloroform:MeOH) to give 22.6 mg of 14  
(78.00% yield). mp 145 °C; [α]21.5D 82.39° (CHCl3)  1H NMR (CDCl3 + TFA): δ 2.05 (1 
H, m), 2.237 (3 H, m), 3.405 (1 H, m), 3.717 (1 H, m), 3.935 (3 H, s), 3.977 (3 H, s), 
3.992 (3 H, s), 4.555 (1 H, dd, J = 3.3 Hz, J = 16.8 Hz), 7.192 (1 H, s), 7.600(1 H, s), 
7.886(1 H, s), 8.045(1 H, s) 13C (CDCl3 + TFA) δ 20.522, 23.038, 51.038, 53.853, 
55.575, 55.659, 55.727, 60.697, 65.838, 103.718, 103.862, 105.224, 107.428, 120.233, 
121.614, 123.177, 124.065, 124.646, 127.324, 147.091, 148.248, 148.798, 149.364, 
158.094, 158.583. EIMS: Calcd for C23H25NO5 m/z 395.1733; found m/z 395.1728. 
Synthesis of  3-acetoxyl-2,6,7-trimethoxy-10,13-dioxo-9,10,11,12,12a,13-hexahydro-
9a-aza-cyclopenta[b]triphenylene (15).  Compound 12 (49.6 mg, 0.1217 mmol), Et3N 
(2 mL, 27.22 mmol), Ac2O (3.5 mL, 31.74 mmol) stirred at room temperature for 3 h.  
The crude mixture was partitioned between CHCl3 and H2O, and the organic layer was 
dried with Na2SO4.  The resulting solution was removed by rotary evaporation and 
separated by column chromatography (98:2 CHCl3:MeOH) to give 50.3 mg of 15 
(91.93% yield). [α]21.5D 138.62° (CHCl3) 1H NMR (CDCl3): δ 2.406 (3 H, s), 2.559 (3 H, 
m), 3.205 (1 H, m), 4.010 (3 H, s), 4.048 (3 H, s), 4.116 (3 H, s), 4.375 (1 H, m), 4.644 (1 
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H, d, J = 18 Hz), 5.689 (1 H, d, J = 18 Hz), 7.229 (1 H, s), 7.718 (1 H, s), 8.092 (1 H, s), 
9.162 (1 H, s) 13C NMR (CDCl3): δ 20.734, 20.768, 30.030, 40.877, 55.947, 56.076, 
56.186, 61.076, 103.152, 104.135, 108.904, 115.673, 121.425, 121.872, 124.198, 
127.362, 128.356, 139.701, 140.031, 149.493, 151.037, 152.209, 169.211, 174.029, 
195.435  EIMS: Calcd for C25H23NO7 m/z 449.1475; found m/z 449.1480       
Synthesis of  3-(4-Acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic acid 
methyl ester (16). Compound 3 (4.9003 g, 14.314 mmol) was added to Et3N (25 mL, 179 
mmol) and Ac2O (50 mL, 529 mmol), and the mixture was stirred at room temperature 
for 1 h.  The solution was rotary evaporated.  The crude product was purified by column 
chromatography (2:1 hexane:EtOAc) to give 5.2195 g of 16 (94.43% yield). mp 110.5–
114.8 °C;  1H NMR (CDCl3): 2.252 (3 H, s), 3.432 (3 H, s), 3.784 (3 H, s), 3.788 (3 H, s), 
3.871 (3 H, s), 6.598 (1 H, d, J = 1.8 Hz), 6.724 (1 H, d, J = 2.1 Hz), 6.753 (1 H, dd, J = 
1.8 Hz, J = 6.3 Hz), 6.780 (1 H, dd, J = 2.1 Hz, J = 6.0 Hz), 6.856 (1 H, d, J = 6.0 Hz), 
6.883 (1 H, d, J = 6.3 Hz), 7.741 (1 H, s); 13C NMR (CDCl3): 20.617, 52.471, 55.306, 
55.871, 55.897, 111.382, 112.607, 113.726, 122.081, 122.540, 124.160, 128.076, 
131.919, 133.364, 139.572, 140.224, 148.662, 149.182, 150.407, 168.334, 168.786. Anal 
Calcd for C21H22O7: C, 65.28; H, 5.74. Found: C, 65.34; H, 5.84.   
Synthesis of 3-Acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylic acid methyl 
ester (17).  Compound 16 (3.9 g, 10 mmol) was dissolved in 36 mL of dry CH2Cl2 and 
cooled to –10 ºC.  A solution of VOF3 (4 g, 32 mmol), 70 mL of CH2Cl2, 35 mL of 
EtOAc, 2 mL of TFA, and 5 drops of TFAA were added dropwise, and the solution was 
allowed to stir at –10 ºC for 4 h.  The solution was poured over ice, and the product was 
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partitioned with CHCl3.  The organic phase was washed with H2O, dried over Na2SO4, 
filtered, and rotary evaporated.  The crude product was purified by column 
chromatography (1:1 hexane:EtOAc) to give 3.5612 g of 17 (91.79% yield). 232.7–234.2 
°C; 1H NMR (CDCl3): 2.407 (3 H, s), 3.955 (3 H, s), 4.002 (3 H, s), 4.050 (3 H, s), 4.070 
(3 H, s), 7.301 (1 H, s), 7.705 (1 H, s), 8.089 (1 H, s), 8.344 (1 H, s), 8.524 (1 H, s); 13C 
NMR (CDCl3): 20.753, 52.164, 55.791, 55.822, 55.947, 102.663, 106.639, 110.187, 
116.101, 123.572, 124.410, 125.465, 126.334, 128.550, 129.874, 141.852, 149.224, 
149.254, 150.013, 168.053, 169.222. Anal. Calcd for C21H20O7: C, 65.62; H, 5.24. Found: 
C, 65.84; H, 5.32.  
Synthesis of 6-hydroxyhexanoic acid amide (18). To a solution of EtOH (500 mL) was 
added caprolactone (50 mL, 451 mmol).  While stirring, NH4OH (100 mL) was added in 
excess, and the solution was allowed to stir at room temperature for 2 days.  The solution 
was then rotory evaporated to a gel and recrystallized from EtOH to give 15 g of 18 (25% 
yield). 1H NMR (CDCl3): 1.363 (2 H, m), 1.628 (4 H, m), 2.285 (2 H, t, J = 7.5 Hz), 
4.034 ( 2 H, t, J = 6.6 Hz); 13C NMR (CDCl3): 24.547, 25.496, 28.307, 34.097, 64.153, 
173.600 Anal. Calcd for C6H13NO2: C, 54.94; H, 9.99; N, 10.68. Found: C, 54.63; H, 
10.01; N, 10.28.      
Synthesis of 6-chlorohexanoic acid amide (19). To a soluton of 18 (2 g, 15 mmol) 60 
mL of dioxane was added SOCl2 (8 mL, 110 mmol). The solution is stirred for 1 h, then 
the solvent was removed by rotary evaporation.  The crude product was purified by 
column chromatography (98:2 CHCl3:MeOH) to give 1.8790 g of 19 (82% yield). 1H 
NMR (CDCl3): 1.461 (2 H, m), 1.643 (2 H, dt, J = 7.5, J = 7.8), 1.769 (2 H, dt, J = 6.6, J 
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= 7.2), 2.221 (2 H, dt, J = 6.6, J = 7.0), 2.221 (2 H, t, J = 7.5), 3.512 (2 H, t, J = 6.6); 13C 
NMR (CDCl3): 24.612, 26.384, 32.204, 35.512, 44.796, 175.452.  Anal. Calcd for 
C6H12ClNO: C, 48.17; H, 8.08; N, 9.36; Cl, 23.70. Found: C, 48.27; H, 7.99; N, 9.24; Cl, 
23.62.   
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